Merck & Co., Inc. Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax
Merck & Co., Inc. (MRK) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax of -$16.00 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-27.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesTax · last filed 2014-02-27
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2013-12-31 was -$4.00M.
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for the quarter ending 2013-09-30 was $0.00.
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2013 was -$16.00M.
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2012 was -$13.00M.
- Merck & Co., Inc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, tax for fiscal 2011 was -$33.00M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 9 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Tax 12 month |
|---|---|---|---|---|
| 2013-12-31 | -$4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$4.00M derived: sum of 2 quarters · filed 2014-02-27 | -$16.00M 10-K · filed 2014-02-27 | |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-07 | -$12.00M 10-Q · filed 2013-11-07 | ||
| 2012-12-31 | -$13.00M 10-K · filed 2014-02-27 | |||
| 2011-12-31 | -$33.00M 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |